| Name | Title | Contact Details |
|---|
St Cloud Hospital Recovery PLS is a Saint Cloud, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Jennings Terrace is a Aurora, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Forest Park Medical Center Frisco is a different kind of hospital. We were built on the principle that healthcare doesn’t have to be uncomfortable. Our hospitals are warm and inviting. Our technology pushes the boundaries of what is possible in medical care. Our surgeons and staff are as exceptional as our services. As a full-service, acute-care hospital, Forest Park Medical Center Frisco focuses on providing high quality outcomes to each and every patient who comes through our doors. It’s time to experience medicine the way it should be experienced. Forest Park Medical Center Frisco. Your destination to better health.
HealthPlan Services (HPS) is the nation’s largest independent provider of sales, benefits administration, retention, reform and technology solutions to the insurance and managed care industries. Headquartered in Tampa, Florida, HPS was founded in 1970 and employs 1,500+ associates. HPS stands at the forefront of the insurance industry, providing exchange connectivity, administration, distribution and technology services to insurers of individual, small group, voluntary and association plans, as well as valuable solutions to thousands of brokers and agents, nationwide. Our Go-To-Exchange® platform combines the services of ExchangeLink, SalesLink, ServiceLink and LoyaltyLink products to enable the connectivity, enrollment, reconciliation, eligibility, subsidy and premium billing, member services and renewals for over 5.0 million members, including 2.4 million members on public exchanges and over 1.2 million members on private exchanges. HPS connects 6 of the nation’s largest insurers to public and state exchanges in 39 states and has a market share of 21%.
Nivalis Therapeutics (formerly N30Pharma) is developing a novel class of disease modifying therapies that preserve intracellular GSNO (S-nitrosoglutathione), a key regulator of organ repair, regeneration, and healing. The Company’s lead program is focused on cystic fibrosis. As the body’s primary reservoir of nitric oxide (NO), GSNO plays a pivotal role in NO signaling. Decreased GSNO levels are associated with inflammatory lung disease, and with increased activity of GSNOR (GSNO reductase), the primary catabolizing enzyme of GSNO. Nivalis Therapeutics has developed a broad portfolio of proprietary, potent, small molecule inhibitors of GSNOR that have been shown to preserve endogenous GSNO levels and to be effective in “gold-standard” models of inflammatory lung disease. Nivalis Therapeutics is located in Boulder, Colorado.